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Abstract
Antimicrobial resistance (AMR) plays an important role in the pathogenesis and spread of Clostridioides difficile infection (CDI), the
leading healthcare-related gastrointestinal infection in the world. An association between AMR and CDI outbreaks is well documented,
however, data is limited to a few ‘epidemic’ strains in specific geographical regions. Here, through detailed analysis of 10330 publicly-
available C. difficile genomes from strains isolated worldwide (spanning 270 multilocus sequence types (STs) across all known evolutionary clades), this study provides the first species-wide snapshot of AMR genomic epidemiology in C. difficile. Of the 10330 C. difficile
genomes, 4532 (43.9%) in 89 STs across clades 1–5 carried at least one genotypic AMR determinant, with 901 genomes (8.7%) carrying
AMR determinants for three or more antimicrobial classes (multidrug-resistant, MDR). No AMR genotype was identified in any strains
belonging to the cryptic clades. C. difficile from Australia/New Zealand had the lowest AMR prevalence compared to strains from Asia,
Europe and North America (P<0.0001). Based on the phylogenetic clade, AMR prevalence was higher in clades 2 (84.3%), 4 (81.5%)
and 5 (64.8%) compared to other clades (collectively 26.9%) (P<0.0001). MDR prevalence was highest in clade 4 (61.6%) which was
over three times higher than in clade 2, the clade with the second-highest MDR prevalence (18.3%). There was a strong association
between specific AMR determinants and three major epidemic C. difficile STs: ST1 (clade 2) with fluoroquinolone resistance (mainly T82I
substitution in GyrA) (P<0.0001), ST11 (clade 5) with tetracycline resistance (various tet-family genes) (P<0.0001) and ST37 (clade 4)
with macrolide-lincosamide-streptogramin B (MLSB) resistance (mainly ermB) (P<0.0001) and MDR (P<0.0001). A novel and previously
overlooked tetM-positive transposon designated Tn6944 was identified, predominantly among clade 2 strains. This study provides a
comprehensive review of AMR in the global C. difficile population which may aid in the early detection of drug-resistant C. difficile strains,
and prevention of their dissemination worldwide.

an estimated ten million deaths and the loss of up to US$210 trillion of annual global income by 2050 [1]. The US Centers for
Disease Control and Prevention (CDC) reported on AMR health
threats in 2013 [2], with an update in 2019 [3], highlighting organisms with the highest AMR burden and threat [3].

DATA SUMMARY
This study utilises publicly available raw sequence reads available
at the NCBI Sequence Read Archive (SRA) as of January 2020.
The details of all genomes are available in the Supplementary Data
(10.6084 /m9.figshare.14623533).

Clostridioides (Clostridium) difficile infection (CDI) causes
major gastrointestinal illness worldwide [4], responsible for
as many as 14 000 deaths annually in the US [2]. C. difficile
has been classified by the CDC as an urgent threat, the
highest threat level, in both the 2013 and 2019 CDC reports,

INTRODUCTION
Antimicrobial resistance (AMR) is one of the biggest threats to
modern medicine. Without focused interventions and collaborations across all government sectors, AMR could be responsible for
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responsible for the highest number of annual deaths among
the pathogens listed [2, 3]. In contrast to other pathogens,
AMR in C. difficile has some unique features. AMR usually
leads to difficulties in treating infections [5], and although
the treatment of CDI is also a challenge [6], such challenge
is not due to AMR per se as resistance to antimicrobials
predominantly used for the treatment of CDI (vancomycin,
metronidazole and fidaxomicin) remains rare [7]. Instead,
AMR plays a significant role in the pathogenesis and spread
of CDI [8], as it allows C. difficile to survive antimicrobial
exposure in the host, while selective pressure allows the
emergence and spread of AMR strains. Several AMR strains
have been associated with outbreaks; PCR ribotype (RT)
017 with clindamycin [9], RTs 017 and 027 with fluoroquinolones [10, 11], RT 027 with rifampicin [12] and RT 078
with tetracyclines [13].

Impact Statement
Utilising a publicly-available database of 10 330 sequence
reads, this study provides the first species-wide evaluation of genotypic AMR in C. difficile. We report the most
common AMR determinants and their genomic neighbourhood, associations between important AMR and
MDR genotypes and specific clades or geographical
regions, and rare AMR genotypes that may have been
missed in earlier studies.

this strain selection bias, pairwise average nucleotide identity
(ANI) of reads from these three STs, as well as ST 2 (n=1153),
the most common strain in C1, were compared using the
Sketch algorithm included in BBtools (https://sourceforge.
net/projects/bbmap/). Reads with an ANI of 99.98% or higher
were considered to be clonal and only one genome from each
clonal complex was included in the final analysis. Based on a
small dataset of 240 C. difficile reads (28680 possible pairs, 531
of which were clonal pairs), this cut-off point had a sensitivity
of 70.1% and a specificity of 76.8% for the detection of clonal
strains as defined by Didelot et al. (data not shown) [17]. The
10330 reads remaining in the dataset are summarised in Table 1.

Using multi-locus sequence typing (MLST), the population
of C. difficile can be divided into five major clades (C1 – C5)
and three smaller cryptic clades (C-I, C-II and C-III). The
three cryptic clades are extremely divergent (Figs 1 and
2a) and likely represent independent species or subspecies
based on the genomic data [14]. Three of the five major
clades contain epidemic sequence types (STs); C2 contains
ST 1 (corresponding to RT 027), C4 contains ST 37 (RT 017)
and C5 contains ST 11 (several RTs, including RT 078) [14].
To date, studies have been conducted on the role of AMR
in the emergence and spread of two epidemic STs, 1 and 11
[10, 12, 13]. A few studies have focused also on C. difficile
ST 37 [9, 11], a third epidemic lineage [15], which shows a
high prevalence of resistance to many antimicrobial classes
[8]. Although these studies provided insights on how AMR
impacts the spread of C. difficile, they are limited to a few
strain types in specific geographical regions, and there has
not been any study of AMR prevalence in the species-wide
population of C. difficile. Here, through detailed analysis of
10 330 publicly-available genomes from C. difficile isolated
worldwide, we provide the first species-wide snapshot of
AMR genomic epidemiology in C. difficile.

Identification of multidrug-resistant C. difficile
Multidrug-resistant (MDR) C. difficile in this study refers to
C. difficile strains with genotypic AMR determinants (both
accessory genes and mutations in chromosomal genes) for at
least three of the following antimicrobial classes: carbapenems,
fluoroquinolones, glycopeptides (vancomycin), nitroimidazoles (metronidazole), oxazolidinones (linezolid), macrolide-
lincosamide-streptogramin B (MLSB), phenicols, rifamycins,
tetracyclines and sulfa-containing agents. Resistance determinants for aminoglycosides and cephalosporins were excluded
from this definition as C. difficile is intrinsically resistant to these
agents [18, 19].

Detection of accessory AMR genes and associated
transposons
To detect the presence of accessory AMR genes, raw sequence
reads were interrogated against ResFinder/ARGannot databases, with an addition of two newly-characterised AMR genes
found in C. difficile, erm(52) and mefH, using SRST2 with
default settings [16, 20–22]. These databases contain over 500
different genes conferring resistance to 15 different antimicrobial classes, covering all AMR genes known to be carried by the
C. difficile population analysed so far [20, 21]. The spectrum
of β-lactamase enzymes detected was confirmed against the
CARD 2020 database [23]. To further characterise the genomic
context of the most common accessory AMR genes, C. difficile
strains with ermB, tetM and tet44 genes were interrogated using
SRST2 against a database of C. difficile transposons carrying
ermB (Tn5398 [GenBank accession AF109075.2], Tn6189
[MK895712.1], Tn6194 [HG475346.1], Tn6215 [KC166248.1]
and Tn6218 [HG002387.1]), tetM (Tn916 [U09422.1], Tn5397

METHODS
Genome collection and de-replication of clonal
strains
The starting point for this analysis was an international collection of 12098 C. difficile Illumina paired-end sequence reads
sourced from the NCBI Sequence Read Archive (SRA, https://
www.ncbi.nlm.nih.gov/sra/) in January 2020. All sequence reads
were screened for contamination using Kraken2 v2.0.8-beta and
only reads with >85% of sequences classified as C. difficile were
included. MLST was confirmed on these raw sequence reads by
SRST2 v0.2.0 with the database available on PubMLST (https://
pubmlst.org/organisms/clostridioides-difficile) as previously
described [14, 16]. This dataset comprised a total of 270 STs
spanning the eight currently described evolutionary clades
with a relatively high number of reads from epidemic strains,
particularly STs 1 (C2; n=2,532), 11 (C5; n=1,185) and 37 (C4;
n=786), many of which were likely to be clonal. To adjust for
2
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Fig. 1. Distribution of resistant and multidrug-resistant (MDR) C. difficile. The UPGMA phylogenetic tree represents a total of 270 STs
included in this study. The black sections indicate that at least one strain in the ST had acquired resistance (AMR) to at least one
antimicrobial class. The red stars indicate that at least one strain in the ST was MDR (i.e. had acquired resistance to at least three
antimicrobial classes). The pie chart in the middle shows the overall prevalence of MDR C. difficile (black), C. difficile resistance to 1–2
antimicrobial classes (dark grey) and pan-susceptible C. difficile (light grey) among 10 330 C. difficile strains. The bar charts below show
the prevalence of resistant and MDR strains in each clade.

[AF333235.1] and Tn6190 [FN665653]) and tet44 (Tn6164
[FN665653]) [24, 25] with 80% minimum coverage and 10%
maximum divergence [16], corresponding with 72% minimum
nucleotide identity (NI).

To detect the presence of a plasmid conferring metronidazole
resistance (pCD-METRO) [26], a custom database was created
consisting of all eight coding sequences (CDS) of pCD-METRO.
SRST2 was used with default settings on all sequence reads
3
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Fig. 2. Summary of antimicrobial resistance genotype of C. difficile. (a) For evolutionary context, a neighbour-joining phylogeny based
on MLST shows the global population structure of C. difficile. (b) The prevalence of C. difficile strains harbouring accessory AMR genes
across different clades (leftmost) and the prevalence of resistance to important antimicrobial classes conferred mainly by accessory
AMR genes. The presence of an aminoglycoside resistance gene (**) does not contribute to the definition of MDR C. difficile. (c) The
prevalence of C. difficile strains having significant amino acid substitutions associated with AMR across different clades (leftmost) and
the prevalence of resistance to important antimicrobial classes conferred mainly by amino acid substitution.

against this customised database [16]. The 23 C. difficile genomes
from the original study [26] were included in the analysis and
used to evaluate the accuracy of the database.

FN538970], M68 [C4, FN668375] and M120 [C5, FN665653]).
C. difficile strains were categorized as resistant to an antimicrobial if they carried a gene allele with at least one significant point
mutation listed in Table 2 [24, 27, 28].

Detection of amino acid substitutions conferring
AMR
All genomes were screened for known point mutations in gyrA,
gyrB, rpoB, pbp1 and pbp3 genes using customised databases in
SRST2. The reference sequences for these genes were obtained
from the PubMLST database (https://pubmlst.org/organisms/
clostridioides-difficile/) as well as reference C. difficile genomes
(CD630 [C1, GenBank accession AM180355], CD196 [C2,

Assessment of AMR prevalence in different
geographical areas
Data on geographical regions of isolation was available
for 6227 (60.3 %) C. difficile strains: Asia (n=355), Europe
(n=3548), North America (n=2212) and Australia/New
Zealand (n=112). The clade distribution was notably
different in these regions (Table 3). Thus, multiple logistic
4
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to an overall 5.7 % [558/9,773] in other clades), over three
times higher than in C2 which had the second-highest
prevalence of MDR strains (356/1951; 18.3 %). The overall
resistance prevalence of important antimicrobial classes is
shown in Fig. 2.

Table 1. C. difficile strains in the de-replicated NCBI database (January
2020)
C.C. difficile clade
C1

No. of genomes (%)

Most prevalent STs

6713 (65.0 %)

ST 2 (9.2 %)*

 

ST 8 (6.0 %)*

 

ST 3 (5.4 %)*

 

ST 42 (4.1 %)*

 

ST 6 (3.2 %)*

 

ST 44 (2.5 %)*

 

ST 14 (2.4 %)*

C2

1951 (18.9 %)

 
C3

237 (2.3 %)

557 (5.4 %)

847 (8.2 %)

ST 11 (7.6 %)*

Fluoroquinolone resistance
Overall, 2959 C. difficile strains (28.6 %) carried known DNA
gyrase substitutions associated with FQR. The prevalence of
FQR was highest in clade C2 (1606/1951; 82.3 %), followed
by C4 (296/557; 53.1 %). Most resistance was conferred by
point substitutions solely within the GyrA subunit of the
enzyme (2771/2959; 93.7 %), followed by point substitutions solely within the GyrB subunit (104/2959; 3.5 %).
Only 2.8 % (84/2959) had substitutions on both gyrase
subunits. The prevalence of GyrB subunit substitution
(both alone and in addition to GyrA substitution) was
highest in C4 (59/557; 10.6 %). The most common GyrA
substitution was Thr82Ile (2843/2855; 99.6 % of strains with
GyrA substitution) and the most common GyrB substitution was Asp426Asn (131/188; 69.7 % of strains with GyrB
substitution), followed by Asp426Val (44/188; 23.4 %), the
latter was almost exclusive to C4 (40/44; 90.9 % of strains
with Asp426Val substitution belonged to C4). Interestingly,
a Ser416Ala substitution, a polymorphism that does not
confer resistance, was found in a majority of C5 (825/847;
94.9 %) and cryptic clades (20/25; 80.0 %), but in only one
clade C1 strain and none of the other major clades.

ST 167 (0.1 %)
25 (0.2 %)

 
Total

ST 37 (4.3 %)*
ST 39 (0.2 %)

 
Cryptic clades

ST 5 (2.0 %)
ST 22 (0.2 %)

 
C5

ST 1 (16.6 %)*
ST 41 (0.8 %)

 
C4

AMR prevalence in different geographical regions
Fig. 3 shows the results of logistic regression analyses of
the clade-adjusted AMR and MDR prevalence compared
to strains from Australia/New Zealand as the reference.
Overall, strains from Asia, Europe and North America all
had higher AMR prevalence (P<0.0001). The difference
in AMR prevalence was most pronounced for fluoroquinolones, where the prevalence of substitution associated
with fluoroquinolone resistance (FQR) in the three continents (collectively 1491/6115; 24.4 %) was estimated to be
at least nine times higher than in Australia/New Zealand
(3/112; 2.7 %). In Asia, Europe and North America, AMR
prevalence was not significantly different, with AMR prevalence in Asia (99/355; 27.9 %) marginally higher than in
Europe (814/3548; 22.9 %) and North America (578/2212;
26.1 %).

ST 361 (<0.1 %)
ST 177 (<0.1 %)

10 330

–

*Ten most prevalent sequence types (STs) in this dataset.
ST, sequence type.

regression analyses were performed using R to assess the
clade-adjusted AMR prevalence for major antimicrobial
classes (MLSB, tetracyclines, fluoroquinolones and rifamycins), as well as MDR prevalence. From the initial analysis,
the overall AMR prevalence was lowest in strains from
Australia/New Zealand. Thus, they were used as the reference group in this analysis.

RESULTS
Summary of AMR and MDR prevalence
Of the 10 330 C. difficile genomes evaluated, 4532 (43.9 %)
contained acquired resistance genes for at least one antimicrobial class, with 89 STs across five major clades having
at least one resistant strain (Fig. 1). A total of 901 strains
(8.7 %) across 28 STs harboured resistance determinants
for three or more antimicrobial classes and were therefore
classified as MDR. Based on resistance prevalence, C. difficile could be divided into clades with an overall resistance
prevalence of ≥50 %, which included C2, C4 and C5, each
of which contained an epidemic ST (ST 1 in C2, ST 37 in
C4 and ST 11 in C5), and clades with an overall resistance
prevalence of <50 %, which included C1 and C3, as well as
all three cryptic clades. The prevalence of MDR C. difficile
was highest in C4 C. difficile (61.6 % [343/557] compared

MLSB resistance
Table 4 summarises the major genotypic determinants
for MLSB antimicrobials detected in our survey. The most
common determinants were ermB (1775 strains, 17.2 %)
followed by erm(52) (145 strains, 1.4 %) and ermG (25
strains, 0.2 %). The erm class genes, which methylate 23S
rRNA and prevent the binding of MLSB antimicrobials,
are associated with high-
level resistance to all MLSB
antimicrobials, as shown by high-level resistance to both
clindamycin and erythromycin [29]. The most common
non-erm genes were mefH (156 strains, 1.5 %), mefA (24
5
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Table 2. Summary of known non-synonymous chromosomal point mutations conferring AMR
Protein

Substitution

Clade distribution*

Comment

C1

C2

C3

C4

C5

Cryptic

Fluoroquinolone resistance
GyrA

Val43Asp

○

○

○

○

○

○

Absent in this dataset

 

Asp71Val

●

○

○

●

○

○

Found in <10 strains in this dataset

 

Asp81Asn

●

○

○

○

○

○

Found in <10 strains in this dataset

 

Thr82Ile

●

●

●

●

●

○

Most common substitution

 

Thr82Val

●

○

○

○

●

○

Found in <10 strains in this dataset

 

Ala118Thr

●

○

○

○

●

○

Found in <10 strains in this dataset

 

Ala384Asp

●

○

○

○

○

○

Found in <10 strains in this dataset

GyrB

Arg377Gly

○

○

○

○

○

○

Absent in this dataset

 

Asp426Asn

●

●

○

●

○

○

Most common substitution

 

Asp426Val

●

○

○

●

○

○

Mostly found in clade 4 C. difficile

 

Arg447Lys

●

●

○

○

●

○

 

Glu466Val

○

○

○

○

●

○

Found in <10 strains in this dataset

RpoB

Asp492Asn

○

○

○

○

○

○

Absent in this dataset

 

Asp492Val

○

○

○

○

○

○

Absent in this dataset

 

His502Asn

●

●

○

●

○

○

 

His502Arg

○

○

○

○

○

○

Absent in this dataset

 

His502Leu

○

○

○

○

○

○

Absent in this dataset

 

His502Tyr

●

○

○

○

○

○

Found in <10 strains in this dataset

 

Arg505Lys

●

●

●

●

●

○

Most common substitution

 

Ser550Phe

●

●

○

○

●

○

Found in <10 strains in this dataset

 

Ser550Tyr

●

●

○

●

○

○

Found in <10 strains in this dataset

Gln1073Arg

○

○

○

○

○

○

Absent in this dataset

 

Rifamycin resistance

 

Fidaxomicin resistance
RpoB

Carbapenem resistance
Pbp1

Leu543His

●

○

○

○

○

○

 

Ala555Thr

●

●

○

●

●

○

Pbp3

Tyr721Ser

●

○

○

●

○

○

 
Most common substitution
 

*Based on significant findings in this study. Solid circles refer to the presence of the substitution in the clade.

strains, 0.2 %), msrD (21 strains, 0.2 %) and lnuC (17 strains,
0.2 %). In total, 1979 C. difficile strains (19.2 %) across 65 STs
(23.9%) in five major clades carried acquired MLSB resistance determinants.

(Table 4). The most common ermB-positive transposon
was Tn6194 (788/1775; 44.4 %; 81.9–100.0 % NI), followed
by Tn6189 (424/1775; 23.9 %; 77.6–99.9 % NI) and Tn6218
(216/1775; 12.2 %; 85.3–100.0 % NI). Tn5398, which
contains two copies of the ermB gene, was found in 170
strains (9.6 %; 81.2–100.0 % NI), most of which belonged
to clade C1 (168/170; 98.8 %).

Among ermB-
positive strains, known ermB-carrying
transposons were identified in 1706 strains (96.5 %) (range,
77.6–100.0 % NI). Transposon diversity was highest in C1
6
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Table 3. Clade distribution in four major geographical regions
Region

Clade
C1

C2

C3

C4

C5

Cryptic

Asia

76.6 %

3.4 %

3.9 %

15.2 %

0.6 %

0.3 %

Europe

74.4 %

11.0 %

3.4 %

2.7 %

8.3 %

0.2 %

North America

68.9 %

24.7 %

0.1 %

2.1 %

4.0 %

0.2 %

Australia/New Zealand

39.3 %

26.8 %

1.8 %

3.6 %

28.6 %

0.0 %

Known tetM-
positive transposons and their variants
were detected in 1245 (86.0 %) tetM-positive C. difficile
(78.0–100.0 % NI). Transposon diversity was highest in
clade C1 (Table 5). The most common transposons were
Tn916 (564/1447; 39.0 %; 83.3–100.0 % NI) and Tn6190
(456/1447; 31.5 %; 81.5–100.0 % NI). In contrast to the
prevalence of ermB-positive transposons above, the distribution of tetM-positive transposons was different in clades
C2, C4 and C5 (Fig. 4a). Known tetM-positive transposons
could not be identified in 78.1 % of tetM-positive clade C2
C. difficile (100/128). Analysis of the assembled genome
of ST1 strain C00008355, a clinical isolate from the UK
[SRA accession ERR347593], showed that the tetM gene
was located on a 9013 bp element with an overall 37.1 % GC
which did not match any transposons in the NCBI database
or published literature (Fig. 4b). The annotated sequence
of this novel Tn, designated Tn6944 by the Liverpool transposon repository [30], was submitted to GenBank and is
available in the DDBJ/ENA/GenBank databases under the
accession number BK013348. Besides tetM, Tn6944 also
carries mefH which encodes a macrolide efflux protein
[22]. Tn6944 was identified in an additional 156 C. difficile
strains (78.0–100.0 % NI), 97 of which belonged to clade C2
(Table 5). All tet44-positive C. difficile harboured Tn6164
(80.3–100.0 % NI), a 100 kbp genomic island containing
tet44 and ant [6]-Ib, a streptomycin resistance determinant
[31].

Tetracycline resistance
Table 5 summarises the genotypic determinants found for
tetracyclines. The most common tetracycline resistance
determinant was tetM (1447 strains, 14.0 %), followed by
tet40 (214 strains, 2.1 %) and tet44 (125 strains, 1.2 %).
These three genes encode ribosomal protection proteins
which prevent the binding of tetracyclines to 16S rRNA. In
total, 1645 C. difficile strains (15.9 %) across 68 STs (25.0 %)
in five major clades carried at least one tet gene, with 333
strains (3.2 %) carrying more than one gene, 81.4 % of which
(271/333) belonged to clade C5. Five ST11 C. difficile strains
(C5) carried four different tet genes, the highest number of
tet genes per genome in this dataset. Interestingly, tet40 and
tet44 were almost exclusively found in clade C5 C. difficile
(94.9 and 98.4 % of tet40- and tet44-positive C. difficile
belonged to C5, respectively).

Vancomycin resistance
A complete vanB operon (vanRB, vanSB, vanYB, vanW,
vanHB, vanB and vanXB genes) was identified in one C. difficile strain, belonging to ST 11 (clade C5). This vanB operon
was previously described to be phenotypically silent due to
a ~2.1 kbp disruption of the vanRB gene which is a response
regulator and part of a key two-component system [32, 33].
This strain was thus considered susceptible to vancomycin.
Metronidazole resistance
SRST2 with the customised pCD-METRO plasmid database
correctly identified the plasmid in 14 C. difficile genomes
from the Boekhoud et al. study [26] (nine belonged to ST
15 and five belonged to ST 2). Apart from these strains, the
pCD-METRO plasmid was found in only one C. difficile
strain belonging to ST15 (clade C1, RT 010, non-toxigenic),
the same RT reported in the Boekhoud et al. study [26].

Fig. 3. Difference in antimicrobial resistance (AMR) prevalence in
different geographical regions. Multiple logistic regression analyses
were performed to compare the clade-adjusted AMR prevalence in four
regions (Asia, Europe, North America and Australia/New Zealand). The
Forest plot represents the estimated AMR prevalence in each continent
compared to Australia/New Zealand.
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Table 4. Summary of resistance determinants for MLSB antimicrobials
Gene

Clade distribution [N (%)]

Overall

C1

C2

C3

C4

C5

Cryptic

ermB

953 (14.2%)

421 (21.6%)

0 (0.0%)

328 (58.9%)

73 (8.6%)

0 (0.0%)

1776
(17.2%)

 Tn5398

168 (2.5%)

1 (0.1%)

0 (0.0%)

0 (0.0%)

1 (0.1%)

0 (0.0%)

170 (1.6%)

 Tn6189

259 (3.9%)

104 (5.3%)

0 (0.0%)

44 (7.9%)

17 (2.0%)

0 (0.0%)

424 (4.1%)

 Tn6194

204 (3.0%)

270 (13.8%)

0 (0.0%)

268 (48.1%)

46 (5.4%)

0 (0.0%)

788 (7.6%)

 Tn6215

106 (1.6%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

2 (0.2%)

0 (0.0%)

108 (1.0%)

 Tn6218

200 (3.0%)

4 (0.2%)

0 (0.0%)

10 (1.8%)

2 (0.2%)

0 (0.0%)

216 (2.1%)

 Unknown

16 (0.2%)

42 (2.2%)

0 (0.0%)

6 (1.1%)

5 (0.6%)

0 (0.0%)

69 (0.7%)

Other erm genes

86 (1.3%)

17 (0.9%)

1
(0.4%)

66 (11.8%)

4 (0.5%)

0 (0.0%)

175 (1.7%)

Non-erm genes

76 (1.1%)

104 (5.3%)

1 (0.4%)

22 (3.9%)

18 (2.1%)

0 (0.0%)

222 (2.1%)

In total, only ten of 223 C. difficile ST 15 strains (4.5 %)
contained the pCD-METRO plasmid.

and 19.4 %, respectively, P=0.2786) than the other clades
(collectively 1.4 %, P<0.0001); 504 C. difficile strains had
a substitution in Pbp1 (492 having A555T and 12 having
L543H), 125 strains had a Y721S substitution in Pbp3 and
12 strains from ST 37 (C4) had substitutions on both Pbp1
(all A555T) and Pbp3.

Rifamycin resistance
Points mutation in rpoB were found in 688 C. difficile
strains (6.7 %), with the highest prevalence in clade C4
(179/557; 32.1 %), followed by C2 (327/1951; 16.8 %). The
most common substitution was Arg505Lys found in 68.0 %
of resistant strains (468/688), followed by His502Asn
(340/688; 49.4 %), with 44.5 % of resistant strains (306/688)
having both substitutions. Besides rifamycins, a Gln1073Arg
substitution in RpoB was also reported to be associated with
reduced susceptibility to fidaxomicin [28]. This substitution
was not detected in this dataset.

In addition to the detection of point substitutions,
carbapenemase-
encoding genes were identified in
two C. difficile strains; an unnamed strain [accession
ERR2703875; ST 2, C1] carried SHV-1 and CD72 [accession SRR5367248; ST 81, C4] carried PER-1. By NCBI
blast approach, the SHV-1 encoding gene was found on
an element resembling a Klebsiella pneumoniae plasmid
tig00001208_pilon [CP036443.1, 99.7 % sequence identity,
35 % coverage] and the PER-1 encoding gene was found
on an element resembling Acinetobacter haemolyticus
plasmid pAHTJR1 [CP038010.1, 99.8 % sequence identity,
5 % coverage].

Carbapenem resistance
A total of 643 C. difficile strains (6.2 %) had substitutions in
either Pbp1 or Pbp3 conferring imipenem resistance, with
the prevalence slightly higher in clades C2 and C4 (21.6
Table 5. Summary of resistance determinants for tetracyclines
Gene

Clade distribution [N (%)]

Overall

C1

C2

C3

C4

C5

Cryptic

tetM

457 (6.8%)

128 (6.6%)

0 (0.0%)

402 (72.2%)

460 (54.3%)

0 (0.0%)

1447 (14.0%)

 Tn916

146 (2.2%)

25 (1.3%)

0 (0.0%)

95 (17.1%)

298 (35.2%)

0 (0.0%)

564 (5.5%)

 Tn5397

215 (3.2%)

1 (0.1%)

0 (0.0%)

1 (0.2%)

8 (0.9%)

0 (0.0%)

225 (2.2%)

 Tn6190

7 (0.1%)

2 (0.1%)

0 (0.0%)

297 (53.3%)

150 (17.7%)

0 (0.0%)

456 (4.4%)

 Tn6944

52 (0.8%)

97 (5.0%)

0 (0.0%)

6 (1.1%)

1 (0.1%)

0 (0.0%)

156 (1.5%)

 Unknown

37 (0.6%)

3 (0.2%)

0 (0.0%)

3 (0.5%)

3 (0.4%)

0 (0.0%)

46 (0.4%)

tet44

2 (<0.1 %)

0 (0.0%)

0 (0.0%)

0 (0.0%)

123 (14.5%)

0 (0.0%)

125 (1.2%)

 Tn6164

2 (<0.1 %)

0 (0.0%)

0 (0.0%)

0 (0.0%)

123 (14.5%)

0 (0.0%)

125 (1.2%)

Other tet genes

129 (1.9%)

12 (0.6%)

2 (0.8%)

14 (2.5%)

336 (39.7%)

0 (0.0%)

493 (4.8%)
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Fig. 4. Clade specificity of tetM-positive transposons in C. difficile. (a) Sankey diagram shows the prevalence of four tetM-positive
transposons commonly found in C. difficile. The left and right axes represent C. difficile clades and the transposons, respectively. The
height of the left axis corresponds to the number of tetM-positive C. difficile strains in each clade, excluding strains with unknown
transposons (clade 1, n=419; clade 2, n=208; clade 4, n=711; clade 4, n=688). (b) The genetic structure of the novel tetM-positive Tn,
Tn6944 [BK013348]. The amino acid sequences of the key elements in this transposon were compared to the elements found in Tn916
[U09422.1].

In addition to the C. difficile class D β-lactamases which
confer intrinsic cephalosporin resistance in C. difficile [18], a
few C. difficile strains also had other classes of β-lactamases.
Forty-three C. difficile strains carried genes encoding
extended-spectrum β-lactamases (ESBL), the most common
type belonging to the TEM family (36 strains), and five strains
carried AmpC β-lactamase genes.

Other resistance types
Genotypic resistance determinants for five other antimicrobials were also identified. First, 124 C. difficile strains (1.2 %)
were positive for the cfrB gene which confers linezolid resistance [34]. Resistance determinants for trimethoprim were
identified in 147 (1.4 %) C. difficile strains, six of which also
harboured sulphonamide resistance determinants. Ninety-
eight C. difficile strains (1.0 %) carried chloramphenicol resistance determinants. The most common determinant was catP
(92/124; 93.9 %).

Finally, 1250 C. difficile strains (12.1 %) carried various
aminoglycoside-resistance determinants. The most common
9
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determinants were aac6-aph2 (666 strains, 6.5 %), aph-III (279
strains, 2.7 %) and sat4 (271 strains, 2.6 %) genes. Notably,
270 strains carried a locus containing aph-III and sat4 genes
adjacent to one another, 68.2 % of which (184/270) belonged
to clade C5 (183 ST 11 strains and one ST 163 strain). This
locus had 99.91 % nucleic acid identity to a gene cluster found
in Erysipelothrix rhusiopathiae, as described in a previous
study [35].

Based on a large sample size, which should give an accurate
representation of the C. difficile population, this study provides
a global atlas of genotypic AMR determinants in C. difficile.
In general, one resistance determinant appeared to dominate
in most antimicrobial classes. For example, ermB and tetM
genes were found in almost 90 % of C. difficile strains with
genotypic resistance to MLSB and tetracycline, respectively.
Fluoroquinolone and rifamycin resistance was also mainly
determined by a single substitution in GyrA (Thr82Ile) and
RpoB (Arg505Lys), respectively. This is similar to other
Gram-positive bacteria, such as Staphylococcus aureus [46],
where one genotypic determinant is responsible for a resistance phenotype in a majority of the bacterial population and
is in contrast to many Gram-negative bacteria, such as several
members in the Enterobacteriaceae [47], where resistance to
an antimicrobial class can be conferred by several genotypic
determinants. The dominance of a single genotypic determinant accommodates the development of genotype-based
rapid detection kits for drug-resistant C. difficile, similar to
real-time PCR assays for methicillin-resistant S. aureus [48].
Such tools can be beneficial for surveillance for C. difficile
outbreaks in the future.

DISCUSSION
The success of several epidemic C. difficile strains is thought
to be associated with an AMR phenotype which provides a
survival advantage for these C. difficile strains in the presence
of antimicrobials while imposing little fitness cost [36–38].
Resistance to several antimicrobial classes has been associated with specific C. difficile lineages: fluoroquinolone and
rifamycin resistance and C. difficile ST 1 (C2) [10, 12], tetracycline resistance and C. difficile ST 11 (C5) [13], as well as
resistance to various antimicrobial classes and MDR and C.
difficile ST 37 (C4) [8]. This study provides genotypic evidence
to support these associations, demonstrated by the higher
resistance prevalence and, especially in the case of tetracycline
resistance in C. difficile ST 11, a higher diversity of resistance
determinants in the associated clades.

Another benefit of large sample size and NGS is the power to
detect rare genotypic determinants. The most notable finding
was the detection of carbapenemase-encoding genes in two
C. difficile strains, STs 2 and 81, comprising approximately
0.02 % of the population. Previously, carbapenem resistance in
C. difficile has been mainly associated with point substitutions
on Pbp1 and Pbp3 which cannot be transferred horizontally
and only confer imipenem resistance [27]. On the contrary,
many carbapenemases provide resistance to a wide range of
carbapenem antimicrobials and are capable of horizontal
transfer [49]. The detection of carbapenemase-encoding
genes is concerning, as C. difficile mainly resides in the colon,
the same habitat as many pathogenic Enterobacteriaceae, and
transfer of these genes could give rise to carbapenem-resistant
Enterobacteriaceae (CRE), another urgent threat in AMR [3].
Conversely, C. difficile can also serve as a reservoir of these
resistance genes. Indeed, the gene encoding SHV-1, one of the
carbapenemases found in this study, was found on an element
similar to a K. pneumoniae plasmid (tig00001208, GenBank
accession CP036443.1; 99.7 % NI), suggesting a possible inter-
phylum transfer event between these two organisms, although
this plasmid was classified as an IncF plasmid according to
PlasmidFinder [50]. Generally, the host range for IncF plasmids is limited to only within the Family Enterobacteriaceae
[51]. Further study is thus needed to confirm that this horizontal transfer is possible.

Although the metadata was not complete (only 60.3 % of
strains had information on geographical origin and there
was inadequate information on host species), some interesting findings can be seen in this genome subset. Fig. 3
demonstrates the difference in AMR prevalence in different
continents which may reflect the use of antimicrobials in
these regions. The most prominent example is fluoroquinolones which are strictly regulated in Australia and New
Zealand but widely used elsewhere [39]. Consequently, there
was a stark difference in the prevalence of FQR between
Australia and the other three regions. Besides fluoroquinolones, the high prevalence of MLSB and tetracycline resistance, especially in Asia, is suggestive of the overuse of these
antimicrobials in the region [40]. We compared the prevalence of AMR genotypes in Australia/New Zealand with
a surveillance study from the same region and found that
the prevalence in this study correlates with the phenotypic
data (P>0.05 for clindamycin [high-level resistance], moxifloxacin and rifaximin resistance) [41]. A similar correlation
was seen when comparing the AMR prevalence in Asia and
North America with studies from Thailand [22] and the
United States [42], respectively. On the contrary, this study
underestimated the AMR prevalence in Europe [43, 44]. It
should be noted that there was a difference in the number of
sequenced strains from various regions. For instance, there
were 3548 strains from Europe, many of which were from
non-clinical sources, and only 112 strains from Australia/
New Zealand in this dataset. As next-generation sequencing
(NGS) becomes more accessible [45] and the collection of
metadata becomes more systematic, a future study should
represent a more complete picture of AMR in the global C.
difficile population.

Recently, two novel resistance determinants for MLSB antimicrobials were found in Asian C. difficile isolates; erm(52) and
mefH [22]. In a larger population of C. difficile, these two genes
were found in 1.4–1.5 % of C. difficile strains, approximately six
times more prevalent than ermG, a gene previously believed
to be the second most prevalent resistance determinant in C.
difficile [8]. Failing to detect these two determinants could
partially explain the discrepancy between resistance genotype
and phenotype in earlier studies [24]. Indeed, the inclusion
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of erm(52) improved the concordance between clindamycin
resistance genotype and high-level clindamycin resistance
phenotype to 100 % and mefH provided concordant genotype
to C. difficile strains with isolated erythromycin resistance
[22]. Further characterisation of mefH revealed that the gene
was located adjacent to tetM on a newly defined transposon
Tn6944 (Fig. 4b). This transposon has also escaped detection and characterisation despite being present mainly in
ST 1 (clade C2), a strain that has been extensively studied
[10, 52]. Interestingly, even though tetracycline resistance was
a key factor in the evolution of the epidemic C. difficile ST 11
due to its use in agricultural practices [13], this antimicrobial
was not included in the antimicrobial susceptibility panel in a
pan-European study [43, 44]. Tetracycline resistance was also
never mentioned in studies involving C. difficile ST 1, perhaps
because the prevalence in this lineage was much lower than
that of FQR mutations (7.1 vs 82.3 %, respectively).

difficile highlights another aspect of AMR in C. difficile; the
role of C. difficile as a reservoir of AMR genes. Aminoglycosides remain a key treatment option for serious staphylococcal
and enterococcal infections, such as infective endocarditis, in
conjunction with β-lactams antimicrobials [57]. Resistance
to aminoglycosides in these pathogens complicates treatment of these infections which may result in adverse clinical
outcomes. Thus, colonisation with C. difficile carrying these
resistance determinants may pose an additional risk of treatment failure in these patients.
This study utilised the direct analysis of raw sequence reads
without the need for genome assembly which enabled the
characterisation of a large dataset within a relatively short
time (approximately 5 min of CPU time [16 cores] per
strain as opposed to more than 30 min of CPU time per
strain for a de novo assembly pipeline). SRST2 provides
rapid MLST and AMR genotyping [16]. SRST2-based
AMR genotyping can be performed using three types of
databases: well-characterised databases of accessory AMR
genes [20, 21, 23], species-specific gene allele databases (e.g.
the PubMLST database), as well as customised databases.
The latter was used in a previous study on a smaller dataset,
the results of which were similar to a standard approach
using blast on annotated draft genomes [58].

A recent study explored the genomic architectures of several
accessory AMR genes in 2190 publicly-available C. difficile
assemblies and suggested that horizontal gene transfer played
a crucial role in the spread of AMR both within C. difficile and
among intestinal bacteria in general [53]. This study provides
more supporting evidence, as there was a high diversity of
ermB-positive transposons throughout the four major clades,
suggesting a constant exchange of genes among the population. Evidence of gene transfer could also be seen among
tetM-positive transposons. For instance, Tn6190 was shared
between C4 and C5, despite their divergence over a million
years ago [14].

Besides the lack of complete metadata, another limitation
of this study was the lack of comparative phenotypic data,
as the study was performed on a publicly-available genome
dataset. However, many key AMR genotypes were reported
to have a high correlation with phenotypic characteristics
[24, 58]. Thus, the prevalence values reported in this
study should reflect the resistance prevalence in C. difficile
population. Also, this study only reports the presence or
absence of genotypic AMR determinants and does not take
into account the different alleles of the genes, as the alleles
were not included in the databases used in the analyses
[20, 21]. Further analyses on the allelic distribution across
C. difficile population may provide additional information
on the spread of AMR genes.

We also identified key antimicrobials, resistance to which
can potentially lead to outbreaks of CDI; fluoroquinolones,
MLSB, rifamycins and tetracyclines, as well as the specific C.
difficile clades associated with such resistance. This provides
an opportunity to develop a focused antimicrobial stewardship policy, targeting specific antimicrobial classes based on
the prevalent C. difficile strains in the region. A real-world
example can be seen in the US, where the reduction of fluoroquinolone use led to a significant reduction in the number
of CDI cases and the associated cost [3].

In conclusion, almost half of C. difficile strains studied
carried at least one genotypic resistant determinant. The
resistance prevalence was higher among clades C2, C4 and
C5 which have been associated with epidemic C. difficile
STs 1, 37 and 11, respectively. Though resistance to antimicrobials for treatment of CDI is rare, this study provides
evidence to support the role of AMR in the spread of C.
difficile, as well as the role of C. difficile as a reservoir of
accessory AMR genes, most notably aminoglycoside resistance determinants and carbapenemase-encoding genes.

As an obligate anaerobe, C. difficile is intrinsically resistant to
aminoglycosides. Additional resistance determinants to these
antimicrobials are not beneficial to the bacterium and are
unlikely to be conserved in the genome. Thus, the presence of
aminoglycoside resistance determinants should reflect recent,
and likely continuous, inter-species gene transfer with taxa in
diverse environments such as the animal gut and soils. The
most common aminoglycoside resistance determinant was
aac6-aph2, a bifunctional gene found in Staphylococcus spp.
and Enterococcus spp. [54], commensal species commonly
found in the human and animal gut. Interestingly, many ST
11 (C5) strains also carried an aph-III and sat4 cluster, a gene
cluster found in E. rhusiopathiae which inhabits the porcine
gut [55], supporting the animal origin and One Health importance of this lineage [35]. Indeed, aminoglycosides have been
heavily used in both agricultural and veterinary practices [56].
The presence of aminoglycoside resistance determinants in C.
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